Obstructive sleep apnea (OSA) is common and has major health implications but treatment
options are limited. In previous research atomoxetine and oxybutynin showed promising effect
at reducing OSA severity, however they reduced arousal threshold, one of the key traits
responsible for OSA. Since oxybutynin was used mainly as a hypnotic, but it is burdened by
several anti-cholinergic side effects, DAW2020, a hypnotic which prolonged the total sleep
time in a previous trial in OSA patients, could be a better candidate to associate with
atomoxetine.